View:
Download DOC
Download PDF
Download XLS
Download XBRL
8-K
false000180886500018088652023-06-202023-06-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2023

 

 

iTeos Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39401

84-3365066

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

321 Arsenal Street

 

Watertown , Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 339 217 0161

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

ITOS

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 20, 2023, Joanne Jenkins Lager, M.D., resigned for personal reasons from her position as the Chief Medical Officer of iTeos Therapeutics, Inc. (the “Company”), effective as of June 23, 2023. Dr. Lager’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or procedures. In connection with Dr. Lager’s resignation, Dr. Lager and the Company expect to enter into a separation agreement that includes a general release of claims (the “Agreement”). Under the Agreement, Dr. Lager would be entitled to receive twelve (12) months of salary continuation, and the Company would pay a portion of her COBRA premiums over the same period. Dr. Lager is also expected to serve as a consultant of the Company. The Company thanks Dr. Lager for her significant contributions, including helping build the Company’s immuno-oncology portfolio and advancing the Company to the current stage of clinical development.

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

iTeos Therapeutics, Inc.

 

 

 

 

Date:

June 26, 2023

By:

/s/ Michel Detheux

 

 

 

Michel Detheux, Ph.D.
President and Chief Executive Officer